Fixed-Dose Niclosamide-Spironolactone Composition for FIP

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a need for an effective antiviral treatment for RNA virus diseases, particularly feline infectious peritonitis in animals, as existing treatments like interferon and ribavirin have been unsuccessful, and GS-441524 is not approved for veterinary use.

Innovation Solution

A combination of niclosamide and spironolactone is administered in a fixed dose pharmaceutical composition to treat RNA virus diseases, with niclosamide ranging from 10 to 300 mg per unit dose and spironolactone from 0.1 to 25 mg per unit dose, administered 3 to 4 times a day, effectively targeting RNA viruses including FCoV and FIP in cats.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If existing antiviral treatments like interferon and ribavirin are used, then treatment is attempted, but they have been unsuccessful in treating RNA virus diseases particularly FIP

Engineering Contradiction:

Improvetreatment success rateVSAvoideffectiveness against RNA viruses

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent combines niclosamide (an anthelmintic drug) and spironolactone (an aldosterone antagonist) into a fixed-dose pharmaceutical composition. This merging of two drugs from different therapeutic categories creates a synergistic effect that successfully treats FIP and other RNA virus infections, resolving the contradiction between treatment reliability and adaptability to RNA viruses.

Inventive Principle:

Principle #5Merging (Combining)

2Reliability

If GS-441524 is used for treatment, then some success is achieved, but it is not approved for veterinary use and is only available as a black-market product

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidavailability and approval status

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent uses niclosamide and spironolactone, which are existing approved veterinary drugs with established safety profiles and availability through legitimate pharmaceutical channels. This approach replaces the need for unapproved, black-market GS-441524 with a legally available combination that achieves similar or better therapeutic outcomes.

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

3Adaptability or versatility

If FCoV infection occurs in cats, then the virus is endemic in the environment, but effective antiviral treatment has been difficult to find

Engineering Contradiction:

Improveprophylaxis capabilityVSAvoidtreatment availability

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The niclosamide-spironolactone combination serves multiple functions: it treats active FIP infections, provides prophylaxis for healthy cats in endemic environments, and is applicable to various RNA virus infections beyond FCoV. This multi-functionality resolves the contradiction between adaptability for prophylaxis and reliability of treatment availability.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentUS20260053819A1Treatment of diseases caused by RNA viruses

Publication Date: 2026.02.26 IMUNEKS FARMA ILAC SAN VE TIC AS

AI summary

The present invention provides a combination comprising niclosamide and spironolactone for use in the treatment of diseases caused by RNA virus in a subject in need thereof. The present invention further provides a combination comprising niclosamide and spironolactone for simultaneous, separate, or sequential use.